Duvelisib (IPI-145, INK1197)

Duvelisib (IPI-145, INK1197)

Cat. No.: DIA-0230948

Size: 50 mg Size: 500 mg Size: Customer Size
Product Information
CAS No. 1201438-56-3
Formula C22H17ClN6O
Molecular Weight 416.86
SMILES CC(NC1=NC=NC2=C1N=C[NH]2)C3=CC4=CC=CC(=C4C(=O)N3C5=CC=CC=C5)Cl
Target PI3K
Product Description Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.
Format & Storage
Purity > 99%
Shipping Shipped on dry ice.
Storage Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month
Solubility Overview Soluble in DMSO
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
logo

Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.

Quick Links
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.
Top